Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Primary objective: to assess the effect of AVE1625 on weight loss over a period of 24 weeks
in abdominally obese patients with atherogenic dyslipidemia. Secondary objectives: - To
assess the dose effect relationship of AVE1625 on HDL-cholesterol and triglycerides plasma
levels over a period of 24 weeks - To assess the efficacy of AVE1625 on secondary parameters
such as waist circumference and other metabolic parameters over a period of 24 weeks - To
assess the safety and tolerabillity of AVE1625 over a period of 24 weeks.